Zenysis
-3%
est. 2Y upside i
Building powerful data analysis software for developing countries.
Rank
#2384
Sector
Healthtech, Data & Analytics, AI
Est. Liquidity
~4Y
Data Quality
Data: LowThe expected 2-year upside is -3%, reflecting a stale valuation, missing growth data, and high dilution risk.
Last updated: July 19, 2026
Exit multiple expands to 12x on IPO or category leadership; projected revenue $8M yields $96M exit. Net 60% after 20% dilution.
Exit multiple converges to 8x typical comp; $64M exit. 20% upside before dilution, net 0% after 20pp dilution.
Multiple compresses to 4x; $32M exit below $53M entry. Net -60% after 20pp dilution; preference stack ($22.4M) partially recovered.
Preference Stack Risk
severeFunding Intensity
42%Total funding $22.4M vs estimated entry valuation $53.2M gives a 42% preference overhang, severely diluting common in downside.
Dilution Risk
highLast round was June 2022; with $22.4M total funding and likely cash burn, a raise within 2 years is probable, diluting existing holders 15-25%.
Secondary Liquidity
noneNo secondary market activity detected; employee equity likely illiquid until exit.
Other — 2 roles
- Careers
- Open Positions · Partnering with governments to solve some of their hardest problems requires strong, multidisciplinary teams and high-quality coordination across diverse domains.
Last updated: March 10, 2026
Questions to Ask at the Interview
Strategic questions based on Zenysis's data — designed to show you've done your homework.
- 1
“How does Zenysis' government sales cycle affect ARR predictability and growth rate?”
- 2
“What is the current ARR and growth trajectory, and what drives renewals?”
- 3
“What is the expected timeline to liquidity, and is there a secondary market for employee equity?”
Community
Valuation Sentiment
Our model estimates -3% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.